Study Group: Zocor Pricing Experts (US)
Council Members in this Study Group: 38
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Contact Gerson Lehrman Group to survey or consult with members of this Study Group
Leading institutions connect with members of this Study Group through GLG
Leading Experts in this Study Group
- Bruce Goldberg
President
Pharmacy Benefit Advisors
Bruce Goldberg is the President of Pharmacy Express Services and Pharmacy Benefit Advisors, both based in Omaha, Nebraska. He is a pharmacist and has experience in managed care with PBM contracting and general pharmacy network management. He developed...
Steven MillerPresident
Steven Miller, MS, DPHSteven Miller, MSPharm, DPH, is the President and Chief Executive Officer of SJM Enterprises, a multi-faceted consumer-response organization, specializing in workers compensation, medication therapy management, and managed care pharmaceutical reimbursement...
Dea BelaziPharmacy Consultant
Dea Belazi, PharmD, MPH, PAHMDea Belazi, PharmD, MPH, PAHM, is currently a Consultant working with health plans and pharmaceutical companies. Dr. Belazi is also a Consulting Practice Leader for Wolters Kluwer Health- Managed Care Group. Previously, he was the Senior Director of Pharmacy...
Tim GallagherExecutive Vice President of Pharmacy Operations
ASTRUP DRUG, INC.Tim Gallagher, RPh, is the Executive Vice President of Pharmacy Operations at Astrup Drug in Minnesota, since 1999. Mr. Gallagher manages all aspects of pharmacy operations for the company. He has been a practicing pharmacist for over 25 years in both...
Joe RennerCEO and part owner
ZYDUS PHARMACEUTICALS USA INCJoseph D. Renner, MBA, is CEO of Zydus Pharmaceuticals (USA) Inc., the US affiliate of Zydus Cadila, an Indian generic pharmaceutical manufacturer. Prior to this, Mr. Renner was the EVP/COO of Geneva Pharmaceuticals, a generics manufacturer and division...
GLG NewsSM Analyses by this Study Group's Leading Experts(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Reverse Payments for PHRMA smell fishy
May 15, 2008
Analysis by: Bruce Goldberg, President,US trade agency wants to end deals delaying generics | www.reuters.com
Our FTC has gone on record once again stating that the so called "Phrma reverse payments" to generic manufacturers breach antitrust regulations. Delaying competition by simply paying off another supplier, leads to higher prices for me, you, and our families. My grandpa used to call this stuff by another term....."shmearing".
-
January 28, 2008
Analysis by: Dea Belazi, Pharmacy Consultant,FDA Receives New Data on Risks of Anemia Drugs | www.fda.gov
Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents. Restrictions will come in the form of prior authorizations and other utilization management techniques.
-
Should We Treat Colds In Children?
November 1, 2007
Cough-Medicine Dilemma Widens | online.wsj.com
An FDA advisory panel recently voted to stop the recommendation of otc cough and cold products in children less than 12 years of age. For decades parents have administered otc cough and could products to infants and young children. Even the FDA Advisory Committee had dissention amongst their members, voting 13 to 9 in favor of the change in the long standing treatment protocol of children's colds.
-
Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it
October 29, 2007
Analysis by: Dea Belazi, Pharmacy Consultant,Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Pfizers failure on Exubera were not of safety issues, or complicated device, or even consumer marketing problems. Their biggest issue that brought failure was the lack of payer coverage. Almost no payer in the US added Exubera to their formulary or saw any value over injectable insulin at the price being commanded by Pfizer.
-
October 22, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Pfizer failed miserably in its attempt to provide diabetic patients with an easy-to-use inhaled insulin as an alternative to injectable insulin. A product they projected would generate sales of $2 billion a year recorded a disappointing $12 million in sales this year. CEO Kindler said he decided to pull the product to spend shareholders' money more wisely. Perhaps he should have thought about that a little sooner.
Members in this Study Group include these company types:
- Pharmacy or Drug Store, Chain
- Pharmacy or Drug Store, Independent/Local
- Consultancy, Pharma-Focused
- Managed Care Health Insurer, Non-Profit
- Managed Care Health Insurer, For-Profit
- Healthcare Management
- Pharmaceuticals Manufacturer
Members in this Study Group often have these job titles:
- Pharmacist - RPh/PharmD
- President
- Owner
- Director
- Principal
- Chief Executive Officer
Related Study Groups
GLG Live Meetings with this Study Group's Leading Experts (?)
July 31, 2007 | Boston
GLGi: Managed Care FormularyJuly 30, 2007 | New York
GLGi: Managed Care FormularyGLG Webcasts & Teleconferences
Leading Experts in Zocor Pricing Experts (US) have not participated in any GLG webcasts.